PHARMACEUTICAL PRICING POLICY PROJECT
|
|
- Aldous Shepherd
- 7 years ago
- Views:
Transcription
1 PHARMACEUTICAL PRICING POLICY PROJECT Executive Summary and Conclusions Valérie Paris Warsaw 19 March 2008
2 OECD pharmaceutical pricing policy project Objective: Assess the cross-national impact of national pricing and reimbursement policies in OECD countries Impact on availability and prices of drugs in other countries Impact on innovation Outputs Case studies: Canada, Mexico, Slovak Republic, Sweden, Switzerland (working papers available on OECD s website) and Germany (forthcoming). Final report to be published in June
3 More than half of OECD countries had per capita spending on pharmaceuticals within ± 20% of the OECD average in 2005 USD PPP United States Canada France Spain Italy Germ any Luxembourg Iceland Japan (1) Portugal Switzerland Australia (1) Austria OECD Norway Hungary (1) Netherlands Finland Czech Republic Slovak Republic Korea Sweden United Kingdom Ireland New Zealand Denmark Poland Mexico 0 Turkey (2 ) (1) 2004; (2) 2003; (3) 2005 pharmaceutical sales per capita Source OECD HEALTH DATA 2007, July 07 3
4 Retail pharmaceutical prices vary between -30% to + 85% of the OECD average Sw itzerland Iceland Canada United States Germany Denmark Norw ay Ireland Japan Italy New Zealand Finland Netherlands Mexico Austria Belgium Luxembourg Sw eden Portugal United Kingdom France Australia Spain Hungary Greece Korea Czech Republic Slovak Republic Turkey Poland Retail price (OECD=100, geometric mean) Note: Prices were converted to a common currency using the 2005 average exchange rate Source: Eurostat-OECD Purchasing Power Parity Programme, 2007, Pharmaceutical Pricing Project Final Report, forthcoming 4
5 Limited cross-national variation is also seen in pharmaceutical consumption levels, but the range is somewhat larger than it is for expenditures Real pharmaceutical expenditure per capita, 2005 pharma PPP (USA =100) France Spain United States Source: Eurostat-OECD Purchasing Power Parity Programme, 2007; OECD Health Data 2007, July 07; Pharmaceutical Pricing Project Final Report, forthcoming Australia (1) Luxembourg Italy Japan (1) Sweden Canada Norway Iceland Germany United Kingdom Portugal Austria Finland OECD Netherlands Korea Ireland Hungary (1) Denmark Switzerland Czech Republic Slovak Republic New Zealand Poland 267 Mexico 120 5
6 Per capita income explains only one quarter of the variability observed in per capita volumes of consumption across OECD countries Real per capita pharamceutical expenditure FRA ESP USA AUS JPN ITA SWE CAN DEU ISL PRT FIN AUT KOR HUN IRL CZE DNK CHE SLK NZL POL NOR R 2 = LUX 100 MEX GDP per capita US$ PPP Note: Data from Japan, Hungary and Australia are from Source: Pharmaceutical Pricing Project Final Report, forthcoming 6
7 Characteristics of pharmaceutical spending Pharmaceutical expenditures increased faster than total health expenditures and faster than GDP between 1980 and 2005 Most rapid period of growth in late 1990s, has since slowed Pharmaceutical expenditures account for 17% of total health expenditures and 1.5% of GDP, on average, in OECD countries but represent about one-third of THE and more than 2% of GDP in Hungary, the Slovak Republic and Portugal Private financing accounts for 40% of pharmaceutical spending in OECD countries The share of expenditure financed out-of-pocket is relatively high, compared to other types of services 7
8 Pharmaceutical market characteristics In 2006, the top 10 firms accounted for nearly 50% of global sales Generic products account for 14% of the global market value, despite accounting for 40% or more of units sold in several of the largest markets --- very significant variation across countries Original products have a longer life-cycle in countries where they do not face significant competition upon patent expiry Prices received by manufacturers for their products vary across countries Japan, Switzerland and the United States have been found to have high exfactory prices for on-patent drugs Nevertheless, convergence of list prices over time has been observed --- especially in Europe, Switzerland, Canada --- and especially for the most innovative products The pharmaceutical industry plays an important role in the economies of several OECD countries (location of headquarters, production facilities, R&D activities) 8
9 The United States account for 45% of worldwide sales, followed by Japan (9%), Germany and France (5%), United Kingdom and Italy (4%) USA JPN FRA DEU GBR ITA ESP CAN ROW Source: IMS Health (2007), Intelligence.360: Global pharmaceutical perspectives
10 1 0 R&D investments and outcomes The output of R&D investments has stabilised at a level lower than was seen during the mid-80 s, despite increased investment, resulting in a decline in R&D productivity Most pharmaceutical innovation is (as in other industries) incremental, with most new products offering little or no added therapeutic value over existing treatments Innovation is perceived as not always aligned with public health priorities
11 1 1 Pharmaceutical industry s strategy The objective is to maximise profit over a product s life cycle, by Launching as quickly as possible in profitable markets Pricing as high as possible according to market conditions and regulatory constraints Trying to extend the period of market exclusivity Engaging in promotional activities to grow the market and gain market share Firms have traditionally sought to maximise their rents by segmenting markets and differentiating their sales prices according to purchasers ability and willingness to pay, within and across countries, to the extent possible
12 1 2 Manufacturers responses to globalisation of the pharmaceutical market The circulation of information on prices and threat of parallel and cross-border trade have reduced opportunities for market segmentation In response, manufacturers have developed strategies, such as: Strategic launch Strategies to reduce parallel trade, where it is permitted, and crossborder trade (such as product proliferation, supply chain management, lobbying, etc.) Strategies to avoid external benchmarking (product proliferation, confidential rebates)
13 1 3 The global market for pharmaceuticals: market power of buyers and sellers Pharmaceutical products are launched in 10 countries, on average No purchaser is in a monopsony position in the global market, as numerous purchasers exist for any given product Patent protection gives firms exclusive rights to manufacture their products, but their monopoly position may be weakened by competition in a therapeutic area Market power of payers/purchasers linked to: The number of covered lives and willingness/ability to pay Insurers ability to influence the volume and mix of drugs used Is the insurer obliged to cover all products meeting criteria for reimbursement? Does the insurer have the ability to designate products as preferred or to restrict coverage to particular circumstances?
14 1 4 Pharmaceutical pricing policy in OECD countries Some countries regulate prices of on-patent drugs to protect consumers against the risk of manufacturers exploiting their monopoly position Many public purchasers set or limit the prices of reimbursed medicines in exchange for subsidy (de facto regulation) Manufacturers have the option of not submitting their products for reimbursement, but instead marketing their products directly to consumers (at the cost of losing insurance subsidy) Free or market-based pricing is often the rule for OTC products and for products that are not reimbursed, rarely also for products that are reimbursed
15 1 5 Techniques used in OECD countries to define or limit prices or reimbursement prices International benchmarking - other payers/purchasers used as a reference Internal referencing other products used as a reference In therapeutic referencing, the price for new products is defined in comparison to therapeutic alternatives Under so-called reference pricing, a common reimbursement level is set for a defined group of products (patients pay the difference) Pharmaco-economic assessment price based on considerations of the product s cost-effectiveness (net benefits against costs) Tendering seller defines price Indirect price control (profit control)
16 1 6 More sophisticated approaches are used on a limited or experimental basis Some countries or purchasers experiment with approaches such as: Product-specific price-volume agreements, especially with products with high risk of overuse or misuse Risk-sharing agreements link the price paid to the outcome for products with high uncertainty as to effectiveness of a product in actual experience
17 Outcomes of price or reimbursement price regulation Regulators often have objectives other than costcontainment (such as ensuring prompt access to effective medicines, support national industry, encourage future innovation, etc.) and do not always seek to obtain the lowest possible price Private payers face strong incentives to negotiate the lowest possible price Outcome depends on relative market power Beyond pricing policy, many other policies affect the pharmaceutical market (marketing authorisation, IPR standards and enforcement, formularies and cost-sharing 1 7
18 1 8 Shortfalls in access to effective medicines exist even in OECD countries Gaps in coverage: in some countries, some people are uninsured or under-insured, even in case of catastrophic expenditures and may face financial barriers Some effective medicines are not subsidised because of budgetary constraints
19 1 9 OECD countries have scope to improve the value for money in their pharmaceutical expenditures Experience from OECD countries demonstrates the potential to: Improve the use of generic alternatives Foster the erosion of off-patent products prices through competition Achieve more efficient distribution systems for prescription and OTC drugs Use more sophisticated reimbursement pricing strategies
20 2 0 Pros and cons of current policies International benchmarking Does not take into account cross-country differences in the value of a product Readily gameable by the pharmaceutical industry Has reduced the ability to price to market and contributed to convergence of list prices, likely resulting in list price inflation Provides manufacturers with incentives to delay launch in lowerpriced markets where there is risk of spill-over Confidential rebates Have been more and more used by purchasers because of international benchmarking and because of the threat of parallel and cross-border trade They create some confusion in international benchmarking, resulting in artificial list prices
21 2 1 Pros and cons of current policies (cont d) Therapeutic referencing can promote value-for-money provided that: Existing alternatives are priced at a level which reflects their value to society Information about the relative «added value» of the new product over existing alternatives is available Reference pricing should have similar attributes, but Consumers may not have information needed to judge relative value and physician decision may not reflect patient preferences Manufacturers may therefore price at common reimbursement level to avoid losing market share If reference price is set too high, it may restrain price competition/generic price erosion by creating a floor
22 2 2 Pros and cons of current policies (cont d) The use of pharmaco-economic assessment Provides policy makers with information needed to define prices that more reflect the value or added value of products to patients or society more broadly Would be expected to result in different prices and expenditures for products across countries, given crosscountry variation in health care needs and preferences, health care costs, etc Is technically challenging and value laden Has proven to be technically and politically feasible in the few countries that employ this tool formally
23 2 3 The link between prices and R&D investments The link between prices and R&D investments is not straightforward R&D investments are motivated by expected returns on investment, which are in turn influenced by expected prices and volumes (since marginal costs of production are relatively low) Absolute and relative prices affect profits. So do volumes of consumption over product life-cycle (affected by rate of uptake and diffusion, competition in the off-patent market, etc ) and costs of doing business (e.g., R&D costs, litigation). Given firms comparative advantages and the state of the art, firms will invest in R&D for products which are expected to be most profitable
24 2 4 Pharmaceutical pricing techniques have the potential to influence expected ROI and future investments International benchmarking encourages product differentiation without therapeutic improvement (product proliferation) Therapeutic referencing and reference pricing encourage investments in product differentiation that provides an improvement over existing products Pharmaco-economic assessment provides incentives for innovation that is valued by patients and society Each country s policy will have a marginal impact on future innovation (depending on its market size), except when there are spill-overs
25 2 5 Main conclusions Pharmacoeconomic assessment offers the most promising opportunity to balance the trade-off between static and dynamic efficiency Price the drug according to its value to society (static efficiency) Promote the right type and level of R&D investments by sending signals to industry as to which innovations are most valued by society and how much value these products offer (dynamic efficiency) Price-volume and risk-sharing agreements are promising approaches to achieve better value-formoney in pharmaceutical spending
26 2 6 Main conclusions (cont d) Stability and consistency of pharmaceutical pricing policies are important since they reduce the risk to manufacturers of responding to current incentives Consistency in the mix of policies used is important to achieve desired outcomes
27 2 7 Three scenarios 1) Status-quo: general continuance of current mix of pricing policies convergence of list prices shortfalls in transparency prices may not well reflect the value offered by products (too low or too high) signals for R&D investment may not result in the outcomes that maximise consumer welfare, in terms of type (orientation) and level of innovation 2) Policy-makers agree that cross-country variations in pharmaceutical prices and expenditures are appropriate forego international benchmarking seek to define prices or expenditures for a given product that reflect the product s assessed value within the country improved affordability in lower-income countries signals for R&D investment should better reward valued innovation 3) R&D is financed through alternative routes and products are purchased at a price equals to the marginal production cost Affordability should be improved Impact on innovation depends on specifics of alternative financing approach Technical and political feasibility of this scenario was not explored
OECD Health Policy Studies. Pharmaceutical Pricing Policies in a Global Market
OECD Health Policy Studies Pharmaceutical Pricing Policies in a Global Market Pharmaceutical Pricing Policies in a Global Market ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT The OECD is a unique
More informationCross-country comparison of health care system efficiency
Cross-country comparison of health care system efficiency Isabelle Joumard, OECD, Economics Department IMF conference, June 21, 2011 Public Health Care Reforms: Challenges and Lessons for Advanced and
More informationB Financial and Human Resources
Chapter B Financial and Human Resources Invested In Education Education at a Glance OECD 2011 203 chapter B Classification of al expenditure Educational expenditure in this chapter is classified through
More informationVULNERABILITY OF SOCIAL INSTITUTIONS
VULNERABILITY OF SOCIAL INSTITUTIONS 2 December 2014 Paris Seminar in Demographic Economics Falilou FALL Senior Economist OECD Economics Department 1 Introduction and outline Social institutions and the
More informationGovernment at a Glance 2015
Government at a Glance 2015 Size of public procurement Strategic public procurement E-procurement Central purchasing bodies 135 Size of public procurement Public procurement refers to the purchase by governments
More informationPrivate Health insurance in the OECD
Private Health insurance in the OECD Benefits and costs for individuals and health systems Francesca Colombo, OECD AES, Madrid, 26-28 May 2003 http://www.oecd.org/health 1 Outline Background, method Overview
More informationPrivate Health insurance in the OECD
Private Health insurance in the OECD Benefits and costs for individuals and health systems Francesca Colombo, OECD AES, Madrid, 26-28 May 2004 http://www.oecd.org/health 1 Outline Q Background, method
More informationEarnings related schemes: Design, options and experience. Edward Whitehouse
Earnings related schemes: Design, options and experience Edward Whitehouse World Bank core course Washington DC, March 2014 Objectives Primary objective: ensuring older people have a decent standard of
More informationDEBT LEVELS AND FISCAL FRAMEWORKS. Christian Kastrop Director of Policy Studies Branch Economics Department
DEBT LEVELS AND FISCAL FRAMEWORKS Christian Kastrop Director of Policy Studies Branch Economics Department Introduction OECD average gross government debt increased from 73% of GDP in 2007 to 111% in 2013.
More informationTransfer issues and directions for reform: Australian transfer policy in comparative perspective
Transfer issues and directions for reform: Australian transfer policy in comparative perspective Peter Whiteford, Social Policy Research Centre, University of New South Wales p.whiteford@unsw.edu.au 1
More informationPrinciples for application of international reference pricing systems
Principles for application of international reference pricing systems International reference pricing (IRP) is a widely used element of price regulation in the vast majority of EU and EFTA countries. While
More informationANTICIPATING POPULATION AGEING CHALLENGES AND RESPONSES. Peter Whiteford Social Policy Division, OECD www.oecd.org www.oecd.
ANTICIPATING POPULATION AGEING CHALLENGES AND RESPONSES Peter Whiteford Social Policy Division, OECD www.oecd.org www.oecd.org/els Outline z z z What is the OECD and what does it do? Anticipating the challenges
More informationPrivate Health Insurance in OECD Countries
Private Health Insurance in OECD Countries Health Insurance for an Expanded Europe: New Public-Private Options The Prague Symposium 2004 Nicole Tapay(Novartis)* *Based on work performed under OECD private
More informationJuly 2015. Figure 1. 1 The index is set to 100 in 2000. House prices are deflated by country CPIs in most cases.
July 2015 Globally, house prices continue a slow recovery. The Global House Price Index, an equally weighted average of real house prices in nearly 60 countries, inched up slowly during the past two years
More informationOECD Health Data 2012 U.S. health care system from an international perspective
OECD Health Data 2012 U.S. health care system from an international perspective Released on June 28, 2012 http://www.oecd.org/health/healthdata Why is the US health spending so high? 5 388 5 270 5 056
More informationCLOSING THE COVERAGE GAP. Robert Palacios, World Bank Pension Core Course March 2014
CLOSING THE COVERAGE GAP Robert Palacios, World Bank Pension Core Course March 2014 Different types of coverage gaps 2 In a subset of richer countries, the main kind of gap is related to adequacy rather
More informationDIGITAL ECONOMY DATA HIGHLIGHTS
DIGITAL ECONOMY DATA HIGHLIGHTS TABLE OF CONTENT The ICT sector: value added, employment, exports and research... 3 Figure 1. Value added of ICT sector and sub-sectors, 213... 3 Figure 2. Employment in
More informationPUBLIC & PRIVATE HEALTH CARE IN CANADA
PUBLIC & PRIVATE HEALTH CARE IN CANADA by Norma Kozhaya, Ph.D. Economist, Montreal Economic Institute before the Canadian Pension & Benefits Institute Winnipeg - June 15, 2007 Possible private contribution
More informationJob quality across OECD countries
HOW GOOD IS YOUR JOB? MEASURING AND ASSESSING JOB QUALITY What makes a good job? Job quality Most people spend a substantial amount of time at work, and work for a significant part of their life. The jobs
More informationrelating to household s disposable income. A Gini Coefficient of zero indicates
Gini Coefficient The Gini Coefficient is a measure of income inequality which is based on data relating to household s disposable income. A Gini Coefficient of zero indicates perfect income equality, whereas
More informationAppendix. Appendix Figure 1: Trends in age-standardized cardiometabolic (CVD and diabetes) mortality by country.
Appendix Appendix Figure 1: Trends in age-standardized cardiometabolic (CVD and diabetes) mortality by country. Men Age standardized cardiometabolic death rate per 100,000 800 700 600 500 400 300 200 800
More informationSpecial Feature: Trends in personal income tax and employee social security contribution schedules
Special Feature: Trends in personal income tax and employee social security contribution schedules TAXING WAGES 211 OECD 212 27 1. Introduction Taxes on labour income including personal income taxes and
More informationPUBLIC VS. PRIVATE HEALTH CARE IN CANADA. Norma Kozhaya, Ph.D Economist, Montreal economic Institute CPBI, Winnipeg June 15, 2007
PUBLIC VS. PRIVATE HEALTH CARE IN CANADA Norma Kozhaya, Ph.D Economist, Montreal economic Institute CPBI, Winnipeg June 15, 2007 Possible private contribution Possible private contribution in the health
More informationHong Kong s Health Spending 1989 to 2033
Hong Kong s Health Spending 1989 to 2033 Gabriel M Leung School of Public Health The University of Hong Kong What are Domestic Health Accounts? Methodology used to determine a territory s health expenditure
More informationHealth Care Systems: Efficiency and Policy Settings
Health Care Systems: Efficiency and Policy Settings Summary in English People in OECD countries are healthier than ever before, as shown by longer life expectancy and lower mortality for diseases such
More informationFDI increases by 25% in 2015, with corporate and financial restructuring playing a large role
FDI IN FIGURES April 2016 FDI increases by 25% in 2015, with corporate and financial restructuring playing a large role In 2015, global FDI flows increased by 25% to USD 1.7 trillion, reaching their highest
More informationTOWARDS PUBLIC PROCUREMENT KEY PERFORMANCE INDICATORS. Paulo Magina Public Sector Integrity Division
TOWARDS PUBLIC PROCUREMENT KEY PERFORMANCE INDICATORS Paulo Magina Public Sector Integrity Division 10 th Public Procurement Knowledge Exchange Platform Istanbul, May 2014 The Organization for Economic
More informationFamily policies and the on-going economic crisis
Family policies and the on-going economic crisis Leave Policies & Research Network meeting, Paris, 17 October 2013 Willem Adema Senior Economist, Social Policy Division, OECD Diverse trends in family outcomes
More information2. Higher education and basic research
2. Higher education and basic research DNK SWE CHE AUT EST FIN ISL CAN NLD AUS ISR CZE NOR PRT DEU BEL JPN FRA EU28 OECD GBR TUR USA KOR IRL NZL ITA ESP GRC SVK SVN POL ZAF HUN LUX CHN CHL MEX RUS Higher
More informationWhat Proportion of National Wealth Is Spent on Education?
Indicator What Proportion of National Wealth Is Spent on Education? In 2008, OECD countries spent 6.1% of their collective GDP on al institutions and this proportion exceeds 7.0% in Chile, Denmark, Iceland,
More informationIndicators and measurement of government policies
1.2.3. Public Value & Policy Analysis and Evaluation Day 11 Indicators and measurement of government policies Compiling indicators Trainer Introduction Mr Jani Heikkinen Head of Division, Statistics Finland
More informationWhat Is the Student-Teacher Ratio and How Big
What Is the Student-Teacher Ratio and How Big Are Classes? The average class in primary education in OECD countries has more than 21 students. Among all countries with available data, this number varies
More informationINCOME INEQUALITY AND GROWTH: THE ROLE OF TAXES AND TRANSFERS
Please cite this paper as: OECD 2012, Income inequality and growth: The role of taxes and transfers, OECD Economics Department Policy Notes, No. 9. January 2012. ECONOMICS DEPARTMENT POLICY NOTE No. 9
More informationA Comparison of the Tax Burden on Labor in the OECD By Kyle Pomerleau
FISCAL FACT Jun. 2014 No. 434 A Comparison of the Tax Burden on Labor in the OECD By Kyle Pomerleau Economist Key Findings Average wage earners in the United States face two major taxes: the individual
More informationHealth Care in Crisis
Health Care in Crisis The Economic Imperative for Health Care Reform James Kvaal and Ben Furnas February 19, 2009 1 Center for American Progress Health Care in Crisis U.S. spends twice as much per capita
More informationSaving New Zealand: Reducing Vulnerabilities and Barriers to Growth and Prosperity
Saving New Zealand: Reducing Vulnerabilities and Barriers to Growth and Prosperity Chart Pack 1 February 211 Savings Working Group Final Report Chart Pack 1 Net foreign liabilities Decades of foreign borrowing
More informationHow many students study abroad and where do they go?
From: Education at a Glance 2012 Highlights Access the complete publication at: http://dx.doi.org/10.1787/eag_highlights-2012-en How many students study abroad and where do they go? Please cite this chapter
More informationORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT
2 OECD RECOMMENDATION OF THE COUNCIL FOR ENHANCED ACCESS AND MORE EFFECTIVE USE OF PUBLIC SECTOR INFORMATION ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT The OECD is a unique forum where the
More informationExpenditure and Outputs in the Irish Health System: A Cross Country Comparison
Expenditure and Outputs in the Irish Health System: A Cross Country Comparison Paul Redmond Overview This document analyzes expenditure and outputs in the Irish health system and compares Ireland to other
More informationFDI gains momentum in second half of 2014
FDI IN FIGURES April 2015 FDI gains momentum in second half of 2014 Global FDI flows picked up in the second half of 2014, increasing 17% in Q3 and 3% in Q4, representing an overall 9% increase in the
More informationHigher education institutions as places to integrate individual lifelong learning strategies
Higher education institutions as places to integrate individual lifelong learning strategies Andrzej Krasniewski Warsaw University of Technology Bologna Expert QUALIFICATIONS FRAMEWORKS AS INSTRUMENTS
More informationAn International Comparison of Pension System Performance in Delivering Adequate Retirement Incomes
An International Comparison of Pension System Performance in Delivering Adequate Retirement Incomes Report by Patricia Pascuzzo, Super Research and Advisory, for Challenger Limited 1 Executive Summary
More informationPOLICY BRIEF. Private Health Insurance in OECD Countries. Introduction. Organisation for Economic Co-operation and Development
POLICY BRIEF Private Health Insurance in OECD Countries September 04 What is the role of private health insurance in OECD countries? Does private health insurance improve access to care and cover? Does
More informationThe U.S Health Care Paradox: How Spending More is Getting Us Less
The U.S Health Care Paradox: How Spending More is Getting Us Less Elizabeth H. Bradley Yale School of Public Health Lauren A. Taylor Harvard Divinity School 1 The paradox Then there's the problem of rising
More informationhttp://mig.tu-berlin.de
Voluntary health insurance in Europe a structured introduction into objectives and status-quo Reinhard Busse, Prof. Dr. med. MPH FFPH Dept. Health Care Management, Technische Universität Berlin (WHO Collaborating
More informationORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT
2 OECD RECOMMENDATION OF THE COUNCIL ON THE PROTECTION OF CRITICAL INFORMATION INFRASTRUCTURES ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT The OECD is a unique forum where the governments of
More informationWhat Is the Total Public Spending on Education?
What Is the Total Public Spending on Education? Indicator On average, OECD countries devote 12.9% of total public expenditure to, but values for individual countries range from less than 10% in the Czech
More informationTax Reform Trends in OECD Countries
OECD 50 TH ANNIVERSARY CHALLENGES IN DESIGNING COMPETITIVE TAX SYSTEMS Paris, 30 June 2011 Tax Reform Trends in OECD Countries 1. Introduction 1. Over the last two decades almost all OECD countries have
More informationTOWARDS HIGH-PERFORMING HEALTH SYSTEMS
The OECD Health Project TOWARDS HIGH-PERFORMING HEALTH SYSTEMS Summary Report ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT Pursuant to Article
More informationThe Wharton School, University of Pennsylvania. Hillsdale College
Real Ways to Drive Down Healthcare Costs Scott E. Harrington The Wharton School, University of Pennsylvania www.scottharringtonphd.com com Free Market Forum Hillsdale College October 1, 2010 Outline The
More informationWaiting times and other barriers to health care access
Dr. Frank Niehaus Wissenschaftliches Institut der PKV (Scientific Research Institute of the Association of German Private Health Insurers) Waiting times and other barriers to health care access 31.8 %
More informationJudicial performance and its determinants: a cross-country perspective
No. 05 JUNE 2013 Judicial performance and its determinants: a cross-country perspective A GOING FOR GROWTH REPORT Box 1. Description of the data The data used in this study come primarily from three
More informationOn What Resources and Services Is Education Funding Spent?
Indicator On What Resources and Services Is Education Funding Spent? In primary, secondary and post-secondary non-tertiary education combined, current accounts for an average of 92% of total spending in
More informationDelegation in human resource management
From: Government at a Glance 2009 Access the complete publication at: http://dx.doi.org/10.1787/9789264075061-en Delegation in human resource management Please cite this chapter as: OECD (2009), Delegation
More informationINEQUALITIES IN HEALTH CARE SERVICES UTILISATION IN OECD COUNTRIES
INEQUALITIES IN HEALTH CARE SERVICES UTILISATION IN OECD COUNTRIES Marion Devaux, OECD Health Division 2014 QICSS International Conference on Social Policy and Health Inequalities, Montreal, 9-May-2014
More informationAgeing OECD Societies
ISBN 978-92-64-04661-0 Trends Shaping Education OECD 2008 Chapter 1 Ageing OECD Societies FEWER CHILDREN LIVING LONGER CHANGING AGE STRUCTURES The notion of ageing societies covers a major set of trends
More informationServices Trade: Recent Policy Trends and Incentives
Services Trade: Recent Policy Trends and Incentives Bernard Hoekman World Bank Based on papers by Borchert and Mattoo (services overall) and Dhar and Srivasta (mode 4) May 27, 2009 Services (should) matter
More informationInternational investment continues to struggle
FDI IN FIGURES December 2014 International investment continues to struggle Figures for the first half of 2014 point to stalled FDI flows Findings FDI fell in the first quarter of 2014 before rebounding
More informationPreventing fraud and corruption in public procurement
Preventing fraud and corruption in public procurement CRIM, European Parliament 24 September 2012 Brussels János Bertók Head of division Public Sector Integrity OECD Data on trends in procurement Size
More informationCountry note China. More than 255 million people in OECD and G20 countries have now attained tertiary education (Table A1.3a).
Education at a Glance 2011 OECD Indicators DOI: http://dx.doi.org/10.1787/eag-2011-en OECD 2011 Under embargo until 13 September, at 11:00 Paris time Education at a Glance 2011 Country note China Questions
More informationIndicator D4 How much time do teachers spend teaching?
Education at a Glance 2014 OECD indicators 2014 Education at a Glance 2014: OECD Indicators For more information on Education at a Glance 2014 and to access the full set of Indicators, visit www.oecd.org/edu/eag.htm.
More informationStructural policy indicators
Economic Policy Reforms Going For Growth Interim Report OECD Chapter Structural policy indicators This chapter contains a comprehensive set of quantitative indicators that allow for a comparison of policy
More informationTrends in the European Investment Fund Industry. in the First Quarter of 2016
Quarterly Statistical Release May 2016, N 65 This release and other statistical releases are available on Efama s website (www.efama.org) Trends in the European Investment Fund Industry in the First Quarter
More informationA Comparison of the Tax Burden on Labor in the OECD
FISCAL FACT July 2015 No. 475 A Comparison of the Tax Burden on Labor in the OECD By Sam Jordan & Kyle Pomerleau Research Assistant Economist Key Findings Average wage earners in the United States face
More informationLucerne, Switzerland 13th-15th July 2007 OVERALL STANDING
OVERALL STANDING Rk Nation Pts. LinzAmster. Lucern W1x M1x W2- M2- W2x M2x M4- LW2x LM2x LM4- W4x M4x W8+ M8+ 1 GBR 161 62 40 59 6 4 4 6 6 3 5 8 8 1 4 4 2 GER 112 47 32 33 6 5 6 4 6 6 3 CHN 101 38 58 5
More informationGlobal Insurance Market Trends
Global Insurance Market Trends November 2011 OECD Insurance and Private Pensions Committee The importance of insurance as a foundation for economic activity was acknowledged at the inception of the OECD
More informationNumber 2 2007. Year 1998. Year 1996. Year 1995. Year 1997
Number 2 2007 PROVIDER PAYMENTS AND COST-CONTAINMENT LESSONS FROM OECD COUNTRIES Historically the OECD countries have struggled to curb their public spending on health care through the use of both demand-oriented
More informationEarly Childhood Education and Care
Early Childhood Education and Care Participation in education by three- and four-year-olds tends now to be high, though coverage is a third or less of the age group in several OECD countries. Early childhood
More informationSpecial Feature: The Tax Treatment of Minimum Wages
Special Feature: The Tax Treatment of Minimum Wages 1. Introduction Binding wage floors can have a significant impact on the wage distribution and the costs faced by employers. International comparisons
More informationFiscal consolidation targets, plans and measures
From: OECD Journal on Budgeting Access the journal at: http://dx.doi.org/10.1787/16812336 Fiscal consolidation targets, plans and measures Please cite this article as: OECD (2011), Fiscal consolidation:
More information41 T Korea, Rep. 52.3. 42 T Netherlands 51.4. 43 T Japan 51.1. 44 E Bulgaria 51.1. 45 T Argentina 50.8. 46 T Czech Republic 50.4. 47 T Greece 50.
Overall Results Climate Change Performance Index 2012 Table 1 Rank Country Score** Partial Score Tendency Trend Level Policy 1* Rank Country Score** Partial Score Tendency Trend Level Policy 21 - Egypt***
More informationThe O rg a n iz ati on f or Economic
In Search Of Value: An International Comparison Of Cost, Access, And Outcomes The still spends more and fares worse on health indicators than most industrialized nations do. by Gerard F. And erso n The
More informationHealth Care a Public or Private Good?
Health Care a Public or Private Good? Keith Schenone December 09, 2012 Economics & Institutions MGMT 7730-SIK Thesis Health care should be treated as a public good because it is not an ordinary commodity
More informationHEALTH CARE DELIVERY IN BRITAIN AND GERMANY: TOWARDS CONVERGENCE?
HEALTH CARE DELIVERY IN BRITAIN AND GERMANY: TOWARDS CONVERGENCE? Background: Two different health care systems Generally speaking, the British and the German health care systems differ not only with respect
More informationSocial insurance, private insurance and social protection. The example of health care systems in some OECD countries
Social insurance, private insurance and social protection. The example of health care systems in some OECD countries References OECD publications on Health care Swiss Re publications Sigma No 6/2007 on
More informationThe OECD s Programme for International Student Assessment
1 The OECD s Programme for International Student Assessment An overview of PISA... 12 What makes PISA unique?... 13 How the assessment takes place... 15 About this manual... 16 11 1 The OECD s Programme
More informationHealth Care Reform in Korea: Key Challenges
Health Care Reform in Korea: Key Challenges IMF Conference October 3, 2011 Soonman KWON, Ph.D. Professor of Health Economics & Policy Sh School of fpbli Public Health Seoul National University, South Korea
More informationTackling income inequality The role of taxes and transfers
From: OECD Journal: Economic Studies Access the journal at: http://dx.doi.org/1.1787/19952856 Tackling income inequality The role of taxes and transfers Isabelle Joumard, Mauro Pisu, Debbie Bloch Online
More informationHow To Calculate Tertiary Type A Graduation Rate
Indicator How Many Students Finish Tertiary Education? Based on current patterns of graduation, it is estimated that an average of 46% of today s women and 31% of today s men in OECD countries will complete
More informationWith data up to: May 2016. Monthly Electricity Statistics
With data up to: 216 Monthly Electricity Statistics Date of publication: 12 ust 216 Monthly Electricity Statistics TABLE OF CONTENTS Page # HIGHLIGHTS i ORGANISATIONAL AND REGIONAL TABLES OECD Total 1
More informationCompetition in manufacturing and service content of manufactured products
Introduction Competition in manufacturing and service content of manufactured products Carolina Lennon 1 Robert Stehrer 2 2 The Vienna Institute for International Economic Studies (wiiw) 1 Paris School
More informationLiteracy Skills for the World of Tomorrow
INSTITUTE FOR STATISTICS Literacy Skills for the World of Tomorrow UNESCO INSTITUTE for STATISTICS FURTHER RESULTS from PISA 2000 Executive Summary [] ORGANISATION for ECONOMIC CO-OPERATION and DEVELOPMENT
More informationSWECARE FOUNDATION. Uniting the Swedish health care sector for increased international competitiveness
SWECARE FOUNDATION Uniting the Swedish health care sector for increased international competitiveness SWEDEN IN BRIEF Population: approx. 9 800 000 (2015) GDP/capita: approx. EUR 43 300 (2015) Unemployment
More informationINTERNATIONAL COMPARISONS OF PART-TIME WORK
OECD Economic Studies No. 29, 1997/II INTERNATIONAL COMPARISONS OF PART-TIME WORK Georges Lemaitre, Pascal Marianna and Alois van Bastelaer TABLE OF CONTENTS Introduction... 140 International definitions
More informationThe paradox of redistribution revisited, or why targeting may matter less than we thought
The paradox of redistribution revisited, or why targeting may matter less than we thought Ive Marx, Lina Salanauskaite and Gerlinde Verbist 8 March 2013 Claim We aim to show that Korpi and Palme s highly
More informationWhat Are the Incentives to Invest in Education?
Indicator What Are the Incentives to Invest in Education? On average across 25 OECD countries, the total return (net present value), both private and public, to a man who successfully completes upper secondary
More informationWhat do we know about income inequality in NZ? (Bryan Perry, MSD) Income inequality: summary indicators
84 What do we know about income inequality in NZ? (Bryan Perry, MSD) Extracts from the 2013 Household Incomes Report, 16 July 2013 Income inequality: summary indicators Income inequality is about how dispersed
More informationBREVE 6 HEALTH BENEFITS PLANS IN OECD COUNTRIES
BREVE 6 HEALTH BENEFITS PLANS IN OECD COUNTRIES Presentation by Valérie Paris. May 2014 A series on policies and methods based on presentations for experts. Prepared by CRITERIA, a knowledge network on
More informationSize and Development of the Shadow Economy of 31 European and 5 other OECD Countries from 2003 to 2015: Different Developments
January 20, 2015 ShadEcEurope31_January2015.doc Size and Development of the Shadow Economy of 31 European and 5 other OECD Countries from 2003 to 2015: Different Developments by Friedrich Schneider *)
More informationInternational comparisons of obesity prevalence
International comparisons of obesity prevalence June 2009 International Comparisons of Obesity Prevalence Executive Summary Obesity prevalence among adults and children has been increasing in most developed
More informationInsurance corporations and pension funds in OECD countries
Insurance corporations and pension funds in OECD countries Massimo COLETTA (Bank of Italy) Belén ZINNI (OECD) UNECE, Expert Group on National Accounts, Geneva - 3 May 2012 Outline Motivations Insurance
More informationOverseas Projection of Fiscal Consolidation, a Working Principle
From: Government at a Glance 11 Access the complete publication at: http://dx.doi.org/10.1787/gov_glance-11-en Fiscal Consolidation The Need for Evidence-Based Decision Making Please cite this chapter
More informationEnergy Efficiency Indicators for Public Electricity Production from Fossil Fuels
international energy agency agence internationale de l energie Energy Efficiency Indicators for Public Electricity Production from Fossil Fuels IEA Information paper In Support of the G8 Plan of Action
More informationINTERNATIONAL COMPARISONS OF HOURLY COMPENSATION COSTS
For release 10:00 a.m. (EST) Tuesday, March 8, 2011 USDL-11-0303 Technical Information: (202) 691-5654 ilchelp@bls.gov www.bls.gov/ilc Media Contact: (202) 691-5902 PressOffice@bls.gov INTERNATIONAL COMPARISONS
More informationWELFARE STATES AND PUBLIC HEALTH: AN INTERNATIONAL COMPARISON. Peter Abrahamson University of Copenhagen pa@soc.ku.dk
WELFARE STATES AND PUBLIC HEALTH: AN INTERNATIONAL COMPARISON Peter Abrahamson University of Copenhagen pa@soc.ku.dk ECLAC,Santiago de Chile, Chile,November 3, 2008 Structure of presentation 1. Health
More informationBelgium (Fr.) Australia. Austria. England. Belgium (Fl.) United States 2. Finland 2. Norway 2. Belgium (Fr.) Australia. Austria Norway 2, 4.
How Much Are Teachers Paid? Indicator The statutory salaries of teachers with at least 15 years of experience average USD 38 914 at the primary level, USD 41 701 at the lower level and USD 43 711 at the
More informationPaul E. Lingenfelter President, State Higher Education Executive Officers
Paul E. Lingenfelter President, State Higher Education Executive Officers Western Interstate Commission on Higher Education Monday, November 5, 2007 Forces Flattening the Global Playing Field Fall of Berlin
More informationPRINCIPLES FOR EVALUATION OF DEVELOPMENT ASSISTANCE
PRINCIPLES FOR EVALUATION OF DEVELOPMENT ASSISTANCE DEVELOPMENT ASSISTANCE COMMITTEE PARIS, 1991 DAC Principles for Evaluation of Development Assistance Development Assistance Committee Abstract: The following
More informationEducation at a Glance 2008. OECD Technical Note For Spain
Education at a Glance 2008 NO MEDIA OR WIRE TRANSMISSION BEFORE 9 SEPTEMBER 2008, 11:00 PARIS TIME OECD Technical Note For Spain Governments are paying increasing attention to international comparisons
More informationAlcohol Consumption in Ireland 1986-2006 A Report for the Health Service Executive
Alcohol Consumption in Ireland 1986-2006 A Report for the Health Service Executive Prepared by Dr. Ann Hope This report should be referenced: Hope, A. (2007). Alcohol consumption in Ireland 1986-2006.
More information